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Abstract
Purpose: Preclinical experiments on large animals are indispensable for evaluating the effectiveness of diabetes
therapies. Miniature swine are well suited for such studies due to their physiological and pathophysiological
responses.
Methods: We compare two methods for inducing diabetes in Goettingen minipigs (GMP), in five with the beta
cell toxin streptozotocin (STZ) and in five other GMP by total pancreatectomy (PE). Glucose homeostasis was
assessed with the intravenous glucose-tolerance test (IVGTT) and continual monitoring of interstitial glucose levels.
At conclusion of the observation period, the pancreata were examined histologically. Three non-diabetic GMP
served as control group.
Results: The IVGTT revealed markedly diabetic profiles in both GMP groups. STZ-GMP were found to harbor
residual C-peptides and scattered insulin-positive cells in the pancreas. PE-GMP survived the total pancreatectomy
only with intensive postoperative care.
Conclusions: Although both methods reliably induced diabetes in GMP, the PE-GMP clearly had more health
problems and required a greater expenditure of time and resources. The PE-GMP model, however, was better at
eliminating endogenous insulin and C-peptide than the STZ-GMP model.
Keywords: diabetes, pig or swine, real-time glucose monitoring, intravenous glucose tolerance test, total pancrea-
tectomy, streptozotocin
Introduction
Neither the physiology of glucose metabolism [1,2] nor
the pathophysiologies of types 1 and 2 diabetes mellitus
[3-8] are fully understood. Among the promising meth-
ods for treating type 1 diabetes is the transplantation of
isolated microencapsulated islets of Langerhans [9,10];
metabolic surgery is one of the recently introduced
treatment options for type 2 diabetes [11,12]. Many
open questions regarding experimental diabetes treat-
ment modalities have been answered in studies using
small animal diabetes models. Such studies, for example,
have answered fundamental questions regarding the
appropriate transplantation site for islets cells [13,14],
the function of islets cell transplants in vivo [15,16], the
recipient immune response to islets cell transplants [17],
and regarding postoperative glucose homeostasis in the
field of diabetes metabolism research [18]. As valuable
as such studies are, however, questions regarding the
feasibility of such concepts under preclinical conditions
can only be answered in large animal models of
diabetes.
Although non-human primates are ideally suited for
such studies due to their genetic and physiological
proximity to humans, ethical considerations and the
personnel required and the high associated costs have
limited primate studies to a very minimum. For training
in the course of transplantation the minipig is a serious
alternative because of its physiological resemblance to
humans, but also due to its size, ease of handling, and
the much lower costs entailed. Because spontaneous dia-
betes is unknown in swine, the diabetes must be
induced. The present study compares two different
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model inducing diabetes chemically with the beta cell
toxin streptozotocin (STZ), the other inducing diabetes
surgically by total pancreatectomy (PE).
Both variants have already been described in the lit-
erature [19-22]. The results with STZ are largely uni-
form: the severity of the induced diabetes depends on
the STZ dosage. The results with PE are less consistent.
Postoperative survival of the animals has been reported
as less than 10 days, which would disqualify PE as a dia-
betes-induction method. But several reports describe
diabetic swine and canines that have undergone PE fol-
lowed by transplantation of islets of Langerhans and
remained free of postoperative complications during a
long term survival of several months [23,24]. The pre-
sent study evaluates and compares the advantages and
disadvantages of each of the two models for diabetes
induction in GMP. The findings will be used to establish
an optimal large animal model for research into specific
questions of diabetes therapy.
Materials and methods
Animals
Ten 11 to 17-month-old female GMP weighing 20-35 kg
were studied. The GMP were housed individually under
standardized conditions (19-23°C; 40-70% relative
humidity; 12:12 hour day/night cycle); they were fed
once daily with a standard swine feed (Altromin; Lage,
Germany); water was provided ad libitum.A l le x p e r i -
ments were approved in advance by the government of
Lower Franconia.
Diabetes induction with STZ
In 5 GMP, 150 mg/kg body weight (bw) of the beta cell
toxin STZ (Sigma-Chemie, Munich, Germany) were
infused via a central venous catheter over 10 min (buf-
fered solution: 1 g STZ in 10 mL sodium citrate buffer
freshly prepared). To avoid hypoglycemia due to insulin
release by the destroyed beta cells, 200 mL 5% glucose
solution were given over one hour after STZ application.
The observation time in this group was 3-4 months.
Diabetes induction with total pancreatectomy
Five GMP underwent total pancreatectomy under gen-
eral anesthesia. After transverse upper abdominal lapar-
otomy, the pancreas tail was carefully detached from the
surrounding tissue. Small vessels originating in the
spleen and the V. portae were ligated and cut. The
spleen was always left intact. Next the corpus and caput
were detached from the surrounding tissue while spar-
ing the pancreaticoduodenal vessels and the vessels sup-
plying the duodenum. Lastly the pancreatic duct was
exposed, double ligated and cut. The abdomen was
closed and once the anesthetic wore off the animal was
returned to its pen where it received intensive medical
care. Over the next 5 days the PE-GMP were given
analgesia with 1 g Novalgin
® (Aventis Pharma; Frankfurt
am Main, Germany) and 3 × 50 mg Tramal
® (Ratio-
pharm; Ulm, Germany) daily. Prophylactic antimicrobial
therapy was also administered with Tazobac
® EF4 g/0.5
g (Wyeth Pharma GmbH; Muenster, Germany). When
feeding was begun on the 6th to 8th postoperative day,
the GMP received an exogenous pancreas enzyme
(Creon
® 25,000 IE/Tag) (Solvay Arzneimittel; Hanover,
Germany) at every feeding. The observation time for
this group was 28 days.
Real time glucose monitoring
The CGMS
® (Medtronic MiniMed; Northridge, USA)
continuous glucose monitoring system was used as
described by us previously [25].
Blood sugar monitoring
All blood sugar readings were done on capillary blood
from the ears. The first drop was discarded; the second
was placed on a test strip of the Ascensia Contour
®
blood glucose monitoring system (Bayer Health Care;
Mishawaka, USA).
Intravenous glucose tolerance test and hyperglycemic
clamp
The intravenous glucose tolerance test (IVGTT) was
performed between the 20th and 28th days after dia-
betes induction. The values of the diabetic GMP were
compared with those of the normoglycemic control
GMP. Feeding and insulin treatment were discontinued
12-16 h before IVGTT was performed. At time point t
= 0 0.5 g/kg bw glucose was injected. At time points t =
- 2 0m i n ;- 1 0 ;0 ;+ 1 ;+ 3 ;+ 5 ;+ 7 ;+ 1 0 ;+ 2 0 ;+ 3 0 ;+ 4 0 ;a n d
+60 min blood samples were taken and the serum insu-
lin and C-peptide levels measured. At the same time
blood glucose levels were determined. For the subse-
quent hyperglycemic clamp in normoglycemic animals,
0.6 g glucose pro kg bw were given at t = +60 min to
raise the blood glucose level above 500 mg/dL, followed
by continuous glucose infusion (2 g/kg bw/hour) to
maintain blood glucose levels at over 500 mg/dL till t =
+100 min, then the infusion was stopped. At t = +90
min 67 mg arginine/kg bw was administered. Blood
samples for monitoring insulin and C-peptide as well as
blood glucose values were taken at time points t = +60
min, +61, +63, +65, +67, +70, +80, +90, +91, +93, +95,
+97, +100 and +110 min. In diabetic GMP there was no
renewed application of glucose solution or continuous
glucose infusion. Arginine was given at t = +60 min.
Blood glucose levels were measured and blood samples
taken at t = +60 min, +61, +63, +65, +67, +70, +80 and
+90 min.
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Page 2 of 10C-peptide RIA
C-peptide was determined in GMP serum samples using
the RIA-Kit (PCP-22K, Linco Research; Missouri, USA).
The resulting radioactivity was measured with a Gamma
counter (Berthold; Bad Wildbad, Germany) in counts
per minute (cpm). C-peptide in ng/mL was calculated
using a standard curve.
Insulin ELISA
Serum insulin levels were measured with a commercial
ELISA-Kit (Biosource; Nivelles, Belgium). The samples
were analyzed at two wavelengths (450 nm and 490 nm)
against a reference filter (650 nm) with the aid of an
ELISA reader (Thermo Max Microplate Reader, MWG
Biotech; Ebersberg, Germany). Insulin levels were mea-
sured on a standard curve and shown in μU/mL.
Histology
At conclusion of the observation time, the pancreata of
the STZ-GMP were removed and 1 cm
3 tissue blocks
from the head, corpus and tail were cryoconserved in
liquid nitrogen. Sections from the different sites of the
pancreas were prepared from these blocks. The sections
were stained with standard hematoxylin-eosin (H&E)
and for standard immunohistochemistry with an
antiinsulin antibody (Guinea pig-anti-swine antiserum;
Dako; Hamburg, Germany).
Statistics
All data are given as mean ± standard deviation (SD).
Results
Glucose metabolism in normoglycemic non-diabetic
control GMP
Continuous interstitial glucose monitoring and glucose
tolerance tests were performed in 3 adult, 11 to 17-
month-old female non-diabetic GMP weighing 20 to 35
kg.
Real-time glucose monitoring in control GMP
RTGM, a system developed to monitor glucose levels in
human diabetics, had been successfully used on GMP by
our group [25]. We applied it in two further GMP mod-
els. The data in Figure 1 confirms the prior result in
one of the two GMP models. The range of values mea-
surable by RTGM is 40 mg/dL to 400 mg/dL. Figure 1
shows that interstitial glucose levels in both the fasting
(< 70 mg/dL) and postprandial (< 100 mg/dL) non-dia-
betic control GMP were lower than in non-diabetic
humans (range: 80-120 mg/dL). After feeding, interstitial
glucose levels in blood rose as expected. In the fasting
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Figure 1 Real time glucose monitoring (RTGM) in a normoglycemic GMP over ca. 20 h; squares: conventional skin puncture blood
glucose measurements; circles: feeding with standard dry feed.
Strauss et al. Diabetology & Metabolic Syndrome 2012, 4:7
http://www.dmsjournal.com/content/4/1/7
Page 3 of 10phase interstitial glucose levels sank temporarily to the
lower measurement limit of 40 mg/dL; it can be specu-
lated that the true value was even lower. The four mea-
surements of blood glucose levels obtained manually by
skin puncture accorded well with those of the RTGM.
Intravenous glucose tolerance test in control GMP
Figure 2 shows blood glucose, insulin and C-peptide
levels in serum of the non-diabetic GMP controls before
and after intravenous stimulation with glucose. All
blood glucose tests were performed exclusively as single
measurements. After glucose injection (0.5 g/kg bw) at t
= 0 with a starting value of 50 mg/dL, blood glucose
levels rose sharply, again attaining almost normoglyce-
mic values with 120 mg/dL at t = +60 min. Within 10
min after glucose injection, C-peptide values increased
twofold and remained constant at the higher level. Insu-
lin rose fivefold within 5 min and also remained con-
tinuously high. During the ensuing hyperglycemic
clamp, continuous application of glucose (initial glucose
bolus of 0.6 g/kg followed by glucose infusion of 2 g/kg/
h), release of insulin and C-peptide rose again and
leveled off at constant values after 10 min. The arginine
bolus (67 mg/kg) given at t = +90 min led to peak insu-
lin and/or C-peptide release independent of glucose.
Glucose metabolism in diabetic STZ-GMP and PE-GMP
Like humans, the GMP were considered to be diabetic if
they had a fasting blood glucose level of > 126 mg/dL (7
mmol/L) or a spontaneous blood glucose level of > 200
mg/dL (11.1 mmol/L). C-peptide values after stimulation
with glucose did not exceed > 0.4 ng/mL.
STZ-induced diabetes
In 5 GMP diabetes was induced with freshly prepared
STZ (150 mg/kg body weight). All 5 STZ-GMP became
diabetic within 24 h after application of STZ. All STZ-
GMP survived STZ application and remained diabetic
over the entire observation period of 3 months. Blood
glucose-adapted insulin therapy was tested in these ani-
mals (see below). Figure 3 shows the IVGTT in 3/5
STZ-GMP. Their blood glucose levels rose rapidly after
intravenous glucose application from the diabetic start-
ing levels (180 mg/dL) to 600 mg/dL and declined
slowly thereafter as expected; only falling to > 350 mg/
dL after 60 min. C-peptide values in serum remained
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Figure 2 Intravenous glucose tolerance test (IVGTT) in normoglycemic GMP (n = 3) with subsequent hyperglycemic clamp and
arginine injection (blue curve). Red curve: C-peptide levels during IVGTT; green curve: insulin levels during IVGTT. Glucose injection at time
point t = 0: 0.5 g/kg bw; glucose injection at t = +60 min: 0.6 g/kg; continual glucose infusion from t = +60 min to t = +100 min: 2 g/kg per
hour; arginine injection at t = +90 min: 67 mg/kg.
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Page 4 of 10constantly under 0.4 ng/mL over the entire period. With
the hyperglycemic clamp (from t = +60 min to t = +80
min) the injection of arginine (67 mg/kg) should have
induced release of residual insulin, but blood glucose
levels showed no appreciable change, although C-pep-
tide rose temporarily to 0.4 ng/mL.
At conclusion of the observation time the pancreata of
the STZ-GMP were explanted and examined histologi-
cally. The pancreata no longer contained intact islets of
Langerhans as in the normoglycemic control animals.
Residual insulin-positive areas were found at different
locations in the sections, possible residue of the once
intact islets of Langerhans. Figure 4 shows the results
for one of the STZ-GMP.
PE-induced diabetes
Diabetes was induced in 5 GMP by total pancreatect-
omy. All PE-GMP survived the surgical procedure and
became diabetic immediately postoperative. Two of the
5 PE-GMP, however, developed an ileus within 4-6 days
postoperative and were removed from the study. Learn-
ing from this experience, we developed a more intensive
postoperative care protocol for the remaining 3/5 PE-
G M P :f r o md a y+ 1t od a y+ 1 4 ,t h er e m a i n i n g3P E -
GMP were given 1 L sterofundin per infusionem,2g
Novalgin and 20 mg Paspertin daily. Each animal was
checked several times daily regarding general health,
vitality, blood glucose levels, and gut noises. The
following steps were also taken: Insulin and a 40% glu-
cose solution (details below) were given daily, both in
dependence on blood glucose levels, potassium (40
mval/d), Neostigmin (0.5 mg/d beginning on day +3
until start of intestinal activity), Tramal (0.7 mg/kg), and
the antibiotic Tazobactam 2 × 4.5 g). The PE-GMP also
received daily exercise therapy to improve their general
health and vitality. A pancreas enzyme (Creon 25.000)
was mixed with their dry feed. Under this intensive regi-
men the PE-GMP began to eat solid feed on their own
on the 4th to 7th day postoperative and began to pass
stool on the 6th to 8th postoperative day. Within 20
days after total pancreatectomy the PE-GMP exhibited
good general health, moved about freely with no com-
plications. In the ensuing time they were given daily
exogenous insulin and exogenous pancreas enzyme.
Under this protocol the PE-GMP survived without com-
plications until the end of the observation period.
Figure 5 shows the IVGTT in the 3 PE-GMP. The
blood glucose immediately rose from high starting
values to > 600 mg/dL, and then fell only slightly over
the next 60 min to about 450 mg/dL. C-peptide
remained < 0.1 ng/mL at every time point and did not
even change after application of glucose and arginine at
t = +60 min.
The weight of the non-diabetic GMP controls
remained constant over a period of 24 days, but the
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Figure 3 IVGTT in diabetic GMP (n = 3) 25 days after diabetes induction with STZ (blue curve); red curve: C-peptide concentrations
during IVGTT. Glucose injection at time point t = 0: 0.5 g/kg; arginine injection at time point t = +60 min: 67 mg/kg.
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Figure 4 Residual beta cells in the pancreas of an STZ-GMP. Pancreas was removed 90 days after STZ-injection; cryosections were stained
with an anti-insulin-antibody. (A) Residual beta cells in the pancreas of an STZ-GMP; (B) Detail from A. (C) Beta cells in the pancreas of a
normoglycemic GMP (positive control); (D) Detail from C.
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Figure 5 IVGTT in PE-GMP (n = 3) 25 days after diabetes induction by total pancreatectomy (blue curve); red curve: C-peptide levels
during the IVGTT. Glucose injection at time point t = 0: 0.5 g/kg; arginine injection at t = +60 min: 67 mg/kg.
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Page 6 of 10diabetic GMP experienced significant weight loss. STZ-
GMP lost 6.95% of their starting weight within 24 days;
PE-GMP lost twice as much at 13.35%. Figure 6 docu-
ments the weight course of all 3 groups over 24 days.
Real-time glucose monitoring
Independent of the method of diabetes induction, all
GMP exhibited a diabetic profile in RTGM. Interstitial
glucose levels in all GMP met the aforementioned dia-
betes criteria (Figure 7). After feeding interstitial glucose
levels rose sharply and reached the upper limit of the
meter at 400 mg/dL, although they may well have been
higher. Following application of insulin, interstitial glu-
cose levels fell as expected in proportion to the dose
given.
Insulin application
In dependence on morning (fasting) blood glucose
levels, the GMP were fed dry feed containing insulin
(Novomix) consisting of 30% insulin-aspart and 70%
intermediary insulin). In the evening (without determin-
ing blood glucose levels), they were given the long-act-
ing insulin Lantus, the dose depending on body weight.
Following this regimen, the diabetic GMP were main-
tained without complications at blood glucose levels
between 200 and 400 mg/dL over several months.
Hypoglycemia was not observed under this protocol.
Total costs
The total costs in personnel and time for feeding, hous-
ing and caring for the two groups of GMP and to
induce diabetes in them are shown in Table 1. STZ-
GMP incurred less overall costs than PE-GMP. STZ-
GMP were cared for beginning on day +1 by a specially
trained animal keeper. In contrast, in the first 14 days
postoperative the PE-GMP received daily care from a
physician experienced in handling postoperative compli-
cations associated with total pancreatectomy. Only after
day +14 when the PE-GMP attained stable good general
health was their daily medical care taken over by an
experience animal keeper.
Discussion
The present study shows that both the STZ-GMP and
PE-GMP models of diabetes induction produced dia-
betic GMP. The RTGM and IVGTT test procedures
reliably measured the diabetic metabolism of the GMP.
Diabetes induction
All GMP treated with STZ became diabetic within 24
hours; this confirms the data in the literature regarding
diabetes induction in GMP using STZ [20]. With regard
to diabetes induction using total pancreatectomy and
the contradictory data in the literature the following can
be said: a) none of our PE-GMP would have survived
the procedure without intensive postoperative care, and
b) only the intensive drug regimen including insulin
application ensured the long-term survival of the PE-
GMP - in our animals for 28 days. Due to the total
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Figure 6 Body weights of a STZ-GMP (red curve) and a PE-GMP (blue curve) during the first 24 days after diabetes induction; an
untreated normoglycemic control GMP (green curve).
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Page 7 of 10absence of endogenous insulin the application of exo-
genous insulin seems to be a critical point to ensure
long term survival in PE-GMP when compared to the
literature [22]. In our experience both diabetes-induc-
tion methods are suited for long-term studies. Before
beginning such a study researchers should intensively
discuss the pros and cons of each model: The PE-GMP
model ensures that no endogenous insulin or C-peptide
will be produced since the cells that release them are
surgically removed, a very important advantage for eva-
luation of the usually still marginal transplant function.
In discussing the drawbacks of the PE-GMP model, a
d i s t i n c t i o nm u s tb em a d eb e t w e e nt h esurgical proce-
dure, postoperative care and physiology. Regarding the
surgical procedure, it entails a great expenditure in time,
technical resources and personnel, and is therefore very
expensive. It requires a surgical team experienced in
total pancreatectomy. The postoperative care is time
intensive and involves tasks that must be performed sev-
eral times daily until the animal has fully recovered from
surgery. The STZ-GMP model, in contrast, can be pro-
duced relatively easily at low cost and the critical phase
of intensive medical care rapidly gives way to the phase
of routine care.
Physiologically the main scientific advantage of the
PE-GMP model, namely the complete elimination of
host insulin production, also entails considerable draw-
backs: Here again a distinction must be made between
surgery-related problems and physiological factors.
Regarding the former the following can be said: The
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Figure 7 RTGM in an STZ-GMP over 60 h. Squares: conventional skin puncture blood glucose measurements; circle: feedings with standard
dry feed; triangles: insulin injections (green: Lantus insulin; red: Novomix insulin).
Table 1 Persons, qualifications and time needed to induce the two diabetes models in the Goettingen minipig and
care for the diabetic animals prior to grafting the isolated islets of Langerhans.
Type of
work
Number of persons
and qualification
Work time
diabetes induction with STZ 1 scientist or surgeon
1 animal caretaker
3 hours
diabetes induction with PE 2 surgeons
1 medical assistant
2 anaesthesiologists
6 hours
management of the
STZ diabetes
1 animal caretaker 2 × 30 minutes/day
management of the PE diabetes (early phase) 1 surgeon Up to 4 hours/day
management of the PE diabetes (late phase) 1 animal caretaker 2 × 30 minutes/day
Abbreviations: STZ: streptozotocin; PE: pancreas explantation in the animal operation theatre (surgical removal of the organ).
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homeostasis of the organism so that the diabetic GMP
has major problems with wound healing and is slow to
recuperate other bodily functions. Physiologically disad-
vantageous are the lack of both the anti-insulin hor-
mone glucagon and the exocrine pancreas enzymes
essential for digestion. STZ-GMP offer the advantage of
ease of diabetes induction (application of central venous
catheter) and no prolonged postoperative recuperation
phase. Injection of STZ selectively destroys beta cells,
leaving the glucagon producing alpha cells intact and
thus lessening the risk of hypoglycemia. The exocrine
pancreas function also remains intact, and feeding and
digestion proceed without complications. The drawback
of the STZ-GMP model is the incomplete destruction of
beta cells, as confirmed in the present study by the his-
tological detection of residual beta cells and the STZ-
GMPs’ partial response to a glucose and arginine bolus
in IVGTT. For transplantation of islets of Langerhans,
therefore, especially if there is inadequate transplant
volume, the PE-GMP model is the superior recipient
model. For research in the field of metabolic surgery
(such as gastric bypass) the STZ-GMS model is better.
The goals of metabolic surgery for improvement of glu-
cose homeostasis are to change the incretin glucagon-
like peptide 1 and glucose-dependent insulinotropic poly-
peptide so as to slow the passage of food and to improve
insulin release and/or stimulate the generation of beta
cells. These goals would be thwarted by prior abdominal
surgery for removal of the pancreas.
Weight
The continual weight loss in diabetic GMP can be
explained by impaired glucose tolerance and is also seen
in type 1 diabetics. The clearly greater weight loss in
PE-GMP can be attributed to the severity of the surgical
intervention and the postoperative drop in food con-
sumption. The control GMP did not gain weight during
the observation period, which was expected since they
were fully grown adults.
Intravenous glucose tolerance test
The IVGTT we used with subsequent hyperglycemic
clamp is a generally accepted procedure for verification
of diabetic disorders [26]. We too could show that this
test for monitoring blood glucose, C-peptide and insulin
levels can reliably identify diabetes in GMP. The various
data however must always be regarded in relation to
o n ea n o t h e r .As i m p l er i s ei ng l u c o s et o l e r a n c ea b o v e
the diabetic threshold is not diagnostic. Independent of
C-peptide levels, residual function of the endocrine pan-
creas may be at play. Unlike blood glucose and C-pep-
tide values, insulin levels in the diabetic GMP lay below
the measurement threshold of the methods we used
(ELISA). In non-diabetic GMP, by contrast, insulin
showed a course comparable to that of C-peptide in
IVGTT.
Real-time glucose monitoring
The RTGM we used is a system developed for the diag-
nosis and control of diabetes. To our knowledge, its use
in swine has only been reported by us [25]; the present
data confirm and add to our previous results. Once
again only measurements are used where the correlation
of interstitial glucose and serum glucose levels was >
90%. The data obtained with RTGM permit two conclu-
sions: 1) RTGM can be successfully applied preclinically
in swine as shown in the correlation between our
RTGM measurements and the event – feeding or insulin
injection – influencing glucose homeostasis. 2) RTGM
measurements mirror the metabolic state and thus pro-
vided valuable evidence regarding the organism’s current
glucose tolerance. An improvement in glucose tolerance
with a slight increase in blood glucose levels after feed-
ing, for example, or a rapid postprandial decline in
blood glucose levels are made readily apparent over the
long-term.
RTGM’s ability to measure long-term trends is a basic
difference to IVGTT, which allows only relatively brief
monitoring for 120 min after glucose bolus. The major
drawback to RTGM in swine though is its limited mea-
surement range of 40-400 mg/dL. This range is ideal for
human diabetics, since an interstitial glucose level below
40 mg/dL is accompanied by somnolence, if not coma.
By nature GMP have lower blood glucose levels than
humans, levels which cannot be detected by the device
we employed. For future GMP studies a modified
RTGM system is urgently needed, one that accommo-
dates the greater natural range of swine.
Conclusion
Both the STZ-GMP and PE-GMP models reliably
induce diabetes in GMP and are thus suited for research
into specific questions regarding type 1 and type 2 dia-
betes and/or for preclinical evaluation. To our knowl-
edge we are the first to show that with appropriate
postoperative care the PE-GMP can be kept without
complications for prolonged periods (week to months),
during which, for example, preparations for successful
transplantation, e.g. the isolation and in vitro culture of
several islets of Langerhans transplants, can be made.
Acknowledgements
The authors thank Mr. A. Reichert, Mr. J. Weinberger and Mr. P. Heuler for
their excellent technical help; and Mrs. L. Stevenson-Knebel for her
assistance in preparing the manuscript. This study was financed in part by
funds from the EU (BARP
+ #NMP3-CT-2003-505614). This publication was
funded by the German Research Foundation (DFG) and the University of
Wuerzburg in the funding programme Open Access Publishing
Strauss et al. Diabetology & Metabolic Syndrome 2012, 4:7
http://www.dmsjournal.com/content/4/1/7
Page 9 of 10Author details
1Department of General, Visceral, Vascular and Pedatric Surgery (Department
of Surgery I)University Hospital of Wuerzburg, Germany.
2Maltese Hospital
and St. Franziskus Hospital, Flensburg, Germany.
3Experimental
Transplantation Immunology, Department of General, Visceral, Vascular and
Paediatric Surgery (Surgical Clinic I), University Hospital of Wuerzburg,
Germany.
4Department of Paediatrics, University Hospital of Wuerzburg,
Germany.
Authors’ contributions
AS designed and performed experiments, analyzed results and wrote the
manuscript; VM designed and performed experiments; CT, IC and VW
performed experiments; ST and CTG provided critical revision of the
manuscript; KU designed experiments, analyzed results and wrote the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 September 2011 Accepted: 5 March 2012
Published: 5 March 2012
References
1. Blaak E: Sex differences in the control of glucose homeostasis. Curr Opin
Clin Nutr Metab Care 2008, 11:500-504.
2. Dumonteil E, Philippe J: Insulin gene: organisation, expression and
regulation. Diabetes Metab 1996, 22:164-173.
3. Turner RC, Hattersley AT, Shaw JT, Levy JC: Type II diabetes: clinical
aspects of molecular biological studies. Diabetes 1995, 44:1-10.
4. Permutt MA, Chiu K, Ferrer J, Glaser B, Inoue H, Nestorowicz A, Stanley CA,
Tanizawa Y: Genetics of type II diabetes. Recent Prog Horm Res 1998,
53:201-216.
5. Malecki MT: Genetics of type 2 diabetes mellitus. Diab Res Clin Pract 2005,
68(Suppl 1):10-21.
6. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP,
Sledge I: Weight and type 2 diabetes after bariatric surgery: systematic
review and metaanalysis. Am J Med 2009, 122:248-256.
7. Knip M, Kukko M, Kulala P, Veijola R, Simell O, Akerblom HK, Ilonen J:
Humoral beta-cell autoimmunity in relation to HLA-defined disease
susceptibility in preclinical and clinical type 1 diabetes. Am J Med Genet
2002, 115:48-54.
8. Larsson K, Elding-Larsson H, Cederwall E, Kockum K, Neiderud J, Sjöblad S,
Lindberg B, Lernmark B, Cilio C, Ivarsson SA, Lernmark A: Genetic and
perinatal factors as risk for childhood type 1 diabetes. Diabetes Metab Res
Rev 2004, 20:429-437.
9. Bretzel RG, Eckhard M, Bendel MD: Pancreatic islet and stem cell
transplantation: new strategies in cell therapy of diabetes mellitus.
Panminerva Med 2004, 46:25-42.
10. Bretzel RG, Jahr H, Eckhard M, Martin I, Winter D, Brendel MD: Islet cell
transplantation today. Langenbecks Arch Surg 2007, 392:239-253.
11. Saliba J, Wattacheril J, Abumrad NN: Endocrine and metabolic response to
gastric bypass. Curr Opin Clin Nutr Metab Care 2009, 12:515-521.
12. Frachetti KJ, Goldfine AB: Bariatric surgery for diabetes management. Curr
Opin Endocrinol Diabetes Obes 2009, 16:119-124.
13. Rajab A, Buss J, Diakoff E, Hadley GA, Osei K, Ferguson RM: Comparison of
the Portal Vein and Kidney Subcapsule as Site for Primate Islet
Autotransplantation. Cell Transplant 2008, 17:1015-1023.
14. van der Windt DJ, Echeverri GJ, Ijzermans JNM, Cooper DKC: The Choice of
the Anatomical Site for Islet Transplantation. Cell Transplant 2008,
17:1005-1014.
15. Cui H, Tucker-Burden C, Cauffiel SM, Barry AK, Iwakoshi NN, Weber CJ,
Safley SA: Lang-term metabolic control of autoimmune diabetes in
spontaneously diabetic nonobese diabetic mice by nonvascularized
microencapsulated adult porcine islets. Transplantation 2009, 88:160-169.
16. Kobayashi T, Arefanian H, Harb G, Tredget EB, Rajotte RV, Korbutt GS,
Rayat GR: Prolonged survival of microencapsulated neonatal porcine islet
xenografts in immune competent mice without antirejection therapy.
Cell Transplant 2008, 17:1243-1256.
17. Truong W, Hancock WW, Anderson CC, Merani S, Shapiro AM: Coinhibitory
T-cell signalling in islet allograft rejection and tolerance. Cell Transplant
2006, 15:105-119.
18. Aguirre V, Stylopoulos N, Grinbaum R, Kaplan LM: An endoluminal sleeve
induces substantial weight loss and normalizes glucose homeostasis in
rats with diet-induced obesity. Obesity 2008, 16:2585-2592.
19. Gäbel H, Bitter-Suermann H, Henriksson C, Säve-Söderbergh J, Lundholm K,
Brynger H: Streptozotocin Diabetes in Juvenile Pigs. Evaluation of an
Experimental Model. Horm Metab Res 1985, 17:275-280.
20. Grüssner R, Nakhleh R, Grüssner A, Tomadze G, Diem P, Sutherland D:
Streptozotocin-induced diabetes mellitus in pigs. Horm Metab Res 1993,
25:199-203.
21. Wilson D, Dhall DP, Simeonovic CJ, Lafferty KJ: Induction and
management of diabetes mellitus in the pig. Aust J Exp Biol Med Sci 1986,
64:489-500.
22. Kobayashi K, Kobayashi N, Okitsu T, Yong C, Fukazawa T, Ikeda H, Kosaka Y,
Narushima M, Arata T, Tanaka N: Development of a porcine model of type
1 diabetes by total pancreatectomy and establishment of a glucose
tolerance evaluation method. Artif Organs 2004, 28:1035-1042.
23. Edamura K, Itakura S, Nasu K, Iwami Y, Ogawa H, Sasaki N, Ohgawara H:
Xenotransplantation of Porcine Pancreatic Endocrine Cells to Total
Pancreatectomized Dogs. J Vet Med Sci 2003, 65:549-556.
24. Morsiani E, Fogli L, Lanza G Jr, Lebow LT, Demetriou AA, Rozga J: Long-
Term Insulin Independence Following Repeated Islet Transplantation in
Totally Pancreatectomized Diabetic Pigs. Cell Transplant 2002, 11:55-66.
25. Strauss A, Tiurbe C, Chodnevskaja I, Thiede A, Timm S, Ulrichs K,
Moskalenko V: Use of the continuous glucose monitoring system in
Goettingen Minipigs, with a special focus on the evaluation of insulin-
dependent diabetes. Transplant Proc 2008, 40:536-539.
26. Rakotoambinina B, Timsit J, Deschamps I, Laborde K, Gautier D, Jos J,
Boitard C, Robert JJ: Insulin responses to intravenous glucose,
intravenous arginine and a hyperglycaemic clamp in ICA-positive
subjects with different degrees of glucose tolerance. Diabetes Metab
1997, 23:43-50.
doi:10.1186/1758-5996-4-7
Cite this article as: Strauss et al.: Goettingen Minipigs (GMP):
Comparison of Two Different Models for Inducing Diabetes. Diabetology
& Metabolic Syndrome 2012 4:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Strauss et al. Diabetology & Metabolic Syndrome 2012, 4:7
http://www.dmsjournal.com/content/4/1/7
Page 10 of 10